Appeals Court Invalidates Bristol-Myers Squibb's Hep B Patent

In a win for the generic drug company Teva Pharmaceuticals and its lawyers at Winston & Strawn, the Federal Circuit knocked out a Bristol-Myers Squibb patent on the Hepatitis B drug Baraclude.

YOUR COMPLIMENTARY 15-DAY LAW.COM TRIAL HAS ENDED.
Subscribe now to continue reading →

To continue reading, upgrade and become a Law.com subscriber.
Get 2 MONTHS FREE when you sign up for a 12 month subscription.